Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Planchard & colleagues in Lancet Oncology.
New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018)
